PDBCode	numPep	title	KeyWords	depDate	releaseDate	expTech	PDBAuthor	refAuthors	refTitle	reference	hetAtoms	Crystallization	Resolution	RFree	RObsv	SpaceGroup	UnitCell	z	seq	len	chainID	molName	numPerCell	EXPRESSION_SYSTEM	ORGANISM_SCIENTIFIC	chainAnno	processNotes
1HXW	1	HIV-1 PROTEASE DIMER COMPLEXED WITH A-84538	ASPARTYL PROTEASE;HYDROLASE;ASPARTIC PROTEINASE;HIV;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	24-JAN-97	04-FEB-98	X-RAY DIFFRACTION	C.H.PARK;V.NIENABER;X.P.KONG	D.J.KEMPF;K.C.MARSH;J.F.DENISSEN;E.MCDONALD;S.VASAVANONDA;;C.A.FLENTGE;B.E.GREEN;L.FINO;C.H.PARK;X.P.KONG	ABT-538 IS A POTENT INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS.	PROC.NATL.ACAD.SCI.USA V. 92 2484 1995	1:RIT	NULL	1.80	NULL	N/A	P 21 21 2	61.06*86.88*46.62(90.00x90.00x90.00)	8	PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF	99	A;B	HIV-1 PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	POL_HV1Z2:P12499:24-122	
1N49	1	VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER ANTI-VIRAL THERAPY	HIV-1 PROTEASE;DRUG RESISTANCE;SUBSTRATE RECOGNITION;INHIBITORBINDING;HYDROLASE;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	30-OCT-02	07-JAN-03	X-RAY DIFFRACTION	M.PRABU-JEYABALAN;E.A.NALIVAIKA;N.M.KING;C.A.SCHIFFER	M.PRABU-JEYABALAN;E.A.NALIVAIKA;N.M.KING;C.A.SCHIFFER	VIABILITY OF A DRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY	J.VIROL. V. 77 1306 2003	2:RIT	SODIUM PHOSPHATE, SODIUM CITRATE, AMMONIUM SULPHATE, PH 6.2, VAPOR DIFFUSION, HANGING DROP	2.20	0.284	N/A	P 1 21 1	51.62*61.35*59.04(90.00x81.20x90.00)	8	PQITLWKRPLVTIRIGGQLKEALLNTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF	99	A;B;C;D	PROTEASE	4	Escherichia coli	Human immunodeficiency virus 1	POL_HV1A2:P03369:57-155	
1RL8	1	CRYSTAL STRUCTURE OF THE COMPLEX OF RESISTANT STRAIN OF HIV-1 PROTEASE(V82A MUTANT) WITH RITONAVIR	ASPARTIC PROTEASE;ASPARTIC PROTEASE-INHIBITOR COMPLEX;RESISTANTSTRAIN;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	25-NOV-03	19-APR-05	X-RAY DIFFRACTION	P.REZACOVA;J.BRYNDA;J.SEDLACEK;J.KONVALINKA;M.FABRY;M.HOREJSI	P.REZACOVA;J.BRYNDA;J.SEDLACEK;J.KONVALINKA;M.FABRY;;M.HOREJSI	CRYSTAL STRUCTURE OF THE COMPLEX OF RESISTANT STRAIN OF HIV-1 PROTEASE(V82A MUTANT) WITH RITONAVIR	TO BE PUBLISHED 2005	1:RIT	50MM MES PH 6.5, 1.8M AMMONIUM SULPHATE, 30% GLYCEROL, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 300K	2.00	0.269	N/A	P 61	61.41*61.41*80.82(90.00x90.00x120.00)	12	PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGAWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF	99	A;B	PROTEASE RETROPEPSIN	2	Escherichia coli bl21(de3)	Human immunodeficiency virus 1	POL_HV1BR:P03367:69-167	
1SH9	1	COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE	HIV-1 PROTEASE;NON-ACTIVE SITE MUTATIONS;ACTIVE SITE MUTATIONS;RITONAVIR;HYDROLASE;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	25-FEB-04	05-OCT-04	X-RAY DIFFRACTION	J.C.CLEMENTE;R.E.MOOSE;R.HEMRAJANI;L.GOVINDASAMY;R.REUTZEL;R.MCKENNA;M.ABANJE-MCKENNA;M.M.GOODENOW;B.M.DUNN	J.C.CLEMENTE;R.E.MOOSE;R.HEMRAJANI;L.R.WHITFORD;;L.GOVINDASAMY;R.REUTZEL;R.MCKENNA;M.AGBANDJE-MCKENNA;;M.M.GOODENOW;B.M.DUNN	COMPARING THE ACCUMULATION OF ACTIVE- AND NONACTIVE-SITE MUTATIONS IN THE HIV-1 PROTEASE.	BIOCHEMISTRY V. 43 12141 2004	1:RIT	20MM SODIUM ACETATE, 1.5 M AMMONIUM SULFATE, PH 6.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K, PH 6.00	2.50	0.279	N/A	P 61	62.12*62.12*84.78(90.00x90.00x120.00)	12	PQITLWQRPLVTIKIGGQLREALLDTGADDTIFEEISLPGRWKPKMIGGIGGFVKVRQYDQIPIEICGHKVIGTVLVGPTPANVIGRNLMTQIGCTLNF	99	A;B	POL POLYPROTEIN	2	Escherichia coli	Human immunodeficiency virus 1	POL_HV1BR:P03367:69-167	
2B60	1	STRUCTURE OF HIV-1 PROTEASE MUTANT BOUND TO RITONAVIR	HIV-1 PROTEASE;PROTEASE INHIBITORS;RITONAVIR;HYDROLASE-HYDROLASEINHIBITOR COMPLEX	29-SEP-05	14-NOV-06	X-RAY DIFFRACTION	J.C.CLEMENTE;L.R.STOW;L.K.JANKA;J.A.JEUNG;K.A.DESAI;L.GOVINDASAMY;M.AGBANDJE-MCKENNA;R.MCKENNA;M.M.GOODENOW;B.M.DUNN	J.C.CLEMENTE;L.R.STOW;L.K.JANKA;J.A.JEUNG;K.A.DESAI;;L.GOVINDASAMY;M.AGBANDJE-MCKENNA;R.MCKENNA;M.M.GOODENOW;;B.M.DUNN	IN VIVO, KINETIC, AND STRUCTURAL ANALYSIS OF THE DEVELOPMENT OF RITONAVIR RESISTANCE	TO BE PUBLISHED	1:GOL; 1:RIT	20 MM SODIUM ACETATE AND 1 M AMMONIUM SULFATE, PH 5.5, VAPOR DIFFUSION, TEMPERATURE 298K	2.20	0.245	N/A	P 61	61.98*61.98*84.25(90.00x90.00x120.00)	12	PQITLWQRPLVTIKIGGQLREALLDTGADDTIFEEISLPGRWKPKMIGGIGGFIKVRQYDQIPIEICGHKVIGTVLVGPTPANIIGRNLMTQIGCTLNF	99	A;B	GAG-POL POLYPROTEIN	2	Escherichia coli	Human immunodeficiency virus 1	Q7SMT3_9HIV1:Q7SMT3:1-99	
3NDW	1	HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:15 COMPLEX STRUCTURE	HIV-1 PROTEASE;HYDROLASE;AIDS;ASPARTYL PROTEASE;SAQUINAVIR;CARBAMYLATION;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	08-JUN-10	20-JUL-11	X-RAY DIFFRACTION	S.GEREMIA;F.M.OLAJUYIGBE;N.DEMITRI	F.M.OLAJUYIGBE;N.DEMITRI;S.GEREMIA	INVESTIGATION OF 2-FOLD DISORDER OF INHIBITORS AND RELATIVE POTENCY BY CRYSTALLIZATIONS OF HIV-1 PROTEASE IN RITONAVIR AND SAQUINAVIR MIXTURES	CRYST.GROWTH DES. V. 11 4378 2011	1:ACT; 3:DMS; 2:NA; 1:RIT; 2:SO4	AMMONIUM SULFATE, DMSO, SODIUM CITRATE, PH 6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.14	N/A	N/A	P 21 21 21	51.25*58.79*61.33(90.00x90.00x90.00)	8	PQITLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGIGGFIKVRQYDQIIIEIAGHKAIGTVLVGPTPVNIIGRNLLTQIGATLNF	99	A;B	PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	Q7SSI0_9HIV1:Q7SSI0:1-99	
3NDX	1	HIV-1 PROTEASE SAQUINAVIR:RITONAVIR 1:50 COMPLEX STRUCTURE	HIV-1 PROTEASE;HYDROLASE;AIDS;ASPARTYL PROTEASE;SAQUINAVIR;CARBAMYLATION;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	08-JUN-10	20-JUL-11	X-RAY DIFFRACTION	S.GEREMIA;F.M.OLAJUYIGBE;N.DEMITRI	F.M.OLAJUYIGBE;N.DEMITRI;S.GEREMIA	INVESTIGATION OF 2-FOLD DISORDER OF INHIBITORS AND RELATIVE POTENCY BY CRYSTALLIZATIONS OF HIV-1 PROTEASE IN RITONAVIR AND SAQUINAVIR MIXTURES	CRYST.GROWTH DES. V. 11 4378 2011	1:CL; 4:DMS; 2:GOL; 1:RIT; 2:SO4	AMMONIUM SULFATE, DMSO, SODIUM CITRATE, PH 6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.03	N/A	N/A	P 21 21 21	51.16*58.57*61.14(90.00x90.00x90.00)	8	PQITLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGIGGFIKVRQYDQIIIEIAGHKAIGTVLVGPTPVNIIGRNLLTQIGATLNF	99	A;B	PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	Q7SSI0_9HIV1:Q7SSI0:1-99	
3NXU	1	CRYSTAL STRUCTURE OF HUMAN CYTOCHROME P4503A4 BOUND TO AN INHIBITOR RITONAVIR	ALPHA BETA PROTEIN;CYTOCHROME P450 FOLD;HEMOPROTEIN;MONOOXYGENASE;CYTOCHROME P450 REDUCTASE;ENDOPLASMIC RETICULUM;OXIDOREDUCTASE-OXIDOREDUCTASE INHIBITOR COMPLEX	14-JUL-10	20-OCT-10	X-RAY DIFFRACTION	I.F.SEVRIOUKOVA;T.L.POULOS	I.F.SEVRIOUKOVA;T.L.POULOS	STRUCTURE AND MECHANISM OF THE COMPLEX BETWEEN CYTOCHROME P4503A4 AND RITONAVIR.	PROC.NATL.ACAD.SCI.USA V. 107 18422 2010	6:DMS; 2:HEM; 2:RIT	100 MM SODIUM MALONATE PH 6.0, 12 % POLYETHYLENE GLYCOL 3350, MICROBATCH UNDER OIL, TEMPERATURE 293K	2.00	0.262	N/A	C 1 2 1	162.12*94.69*93.13(90.00x124.25x90.00)	8	MAYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGAHHHH	485	A;B	CYTOCHROME P450 3A4	2	Escherichia coli	Homo sapiens	CP3A4_HUMAN:P08684:25-503	
3PRS	1	ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR	HYDROLASE-HYDROLASE INHIBITOR COMPLEX	30-NOV-10	26-OCT-11	X-RAY DIFFRACTION	H.KOESTER;A.HEINE;G.KLEBE	J.BEHNEN;H.KOSTER;G.NEUDERT;T.CRAAN;A.HEINE;G.KLEBE	EXPERIMENTAL AND COMPUTATIONAL ACTIVE SITE MAPPING AS A STARTING POINT TO FRAGMENT-BASED LEAD DISCOVERY.	CHEMMEDCHEM V. 7 248 2012	1:1PE; 1:DMS; 1:GOL; 1:PGE; 1:RIT	0.1M NH4AC, 0.1M ACETATE-BUFFER, 26% PEG 4000, PH 4.6, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 289K	1.38	N/A	N/A	P 1 21 1	45.34*72.70*52.30(90.00x108.89x90.00)	2	STGSATTTPIDSLDDAYITPVQIGTPAQTLNLDFDTGSSDLWVFSSETTASEVDGQTIYTPSKSTTAKLLSGATWSISYGDGSSSSGDVYTDTVSVGGLTVTGQAVESAKKVSSSFTEDSTIDGLLGLAFSTLNTVSPTQQKTFFDNAKASLDSPVFTADLGYHAPGTYNFGFIDTTAYTGSITYTAVSTKQGFWEWTSTGYAVGSGTFKSTSIDGIADTGTTLLYLPATVVSAYWAQVSGAKSSSSVGGYVFPCSATLPSFTFGVGSARIVIPGDYIDFGPISTGSSSCFGGIQSSAGIGINIFGDVALKAAFVVFNGATTPTLGFASK	330	A	ENDOTHIAPEPSIN	1	Unknown	Cryphonectria parasitica	CARP_CRYPA:P11838:90-419	
3Q70	1	SECRETED ASPARTIC PROTEASE IN COMPLEX WITH RITONAVIR	HYDROLASE-HYDROLASE INHIBITOR COMPLEX	04-JAN-11	04-JAN-12	X-RAY DIFFRACTION	H.KOESTER;A.HEINE;G.KLEBE	H.KOESTER;A.HEINE;G.KLEBE	THE BINDINGMODE OF HIV-1 PROTEASE INHIBITORS TO PEPSIN-LIKE ASPARTIC PROTEINASES	TO BE PUBLISHED	1:MRD; 1:RIT; 2:ZN	9 MM ZNAC, 16% PEG 8000, 0.1M IMIDAZOLE/MALATE BUFFER PH 6.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 289K	1.40	N/A	N/A	P 21 21 21	49.28*65.46*98.45(90.00x90.00x90.00)	4	QAVPVTLHNEQVTYAADITVGSNNQKLNVIVDTGSSDLWVPDVNVDCQVTYSDQTADFCKQKGTYDPSGSSASQDLNTPFKIGYGDGSSSQGTLYKDTVGFGGVSIKNQVLADVDSTSIDQGILGVGYKTNEAGGSYDNVPVTLKKQGVIAKNAYSLYLNSPDAATGQIIFGGVDNAKYSGSLIALPVTSDRELRISLGSVEVSGKTINTDNVDVLLDSGTTITYLQQDLADQIIKAFNGKLTQDSNGNSFYEVDCNLSGDVVFNFSKNAKISVPASEFAASLQGDDGQPYDKCQLLFDVNDANILGDNFLRSAYIVYDLDDNEISLAQVKYTSASSISALT	342	A	CANDIDAPEPSIN-2	1	Unknown	Candida albicans	CARP2_CANAL:P28871:57-398	
3TNE	1	THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR	ASPARTIC ACID ENDOPEPTIDASES;CATALYTIC DOMAIN;RITONAVIR;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	01-SEP-11	07-MAR-12	X-RAY DIFFRACTION	J.DOSTAL;J.BRYNDA;O.HRUSKOVA-HEIDINGSFELDOVA;P.PACHL;I.PICHOVA;P.REZACOVA	J.DOSTAL;J.BRYNDA;O.HRUSKOVA-HEIDINGSFELDOVA;P.PACHL;;I.PICHOVA;P.REZACOVA	THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR.	J ENZYME INHIB MED CHEM V. 27 160 2012	2:RIT	100-FOLD MOLAR INHIBITOR EXCESS, CPR= 20MG/ML; DROPS: 0.002ML PROTEIN + 0.001ML RESERVOIR; RESERVOIR: 0.1M MES PH 6.5, 30% V/V PEG 400, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 292K	2.40	0.317	0.257	P 21 21 21	61.87*61.61*157.77(90.00x90.00x90.00)	8	DSISLSLINEGPSYASKVSVGSNKQQQTVIIDTGSSDFWVVDSNAQCGKGVDCKSSGTFTPSSSSSYKNLGAAFTIRYGDGSTSQGTWGKDTVTINGVSITGQQIADVTQTSVDQGILGIGYTSNEAVYDTSGRQTTPNYDNVPVTLKKQGKIRTNAYSLYLNSPSAETGTIIFGGVDNAKYSGKLVAEQVTSSQALTISLASVNLKGSSFSFGDGALLDSGTTLTYFPSDFAAQLADKAGARLVQVARDQYLYFIDCNTDTSGTTVFNFGNGAKITVPNTEYVYQNGDGTCLWGIQPSDDTILGDNFLRHAYLLYNLDANTISIAQVKYTTDSSISAV	339	A;B	SECRETED ASPARTIC PROTEASE	2	Unknown	Candida parapsilosis	B8YPM3_CANPA:B8YPM3:63-401	
4EYR	1	CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE 769 HIV-1 PROTEASE IN COMPLEX WITH RITONAVIR	PROTEASE;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	01-MAY-12	30-JAN-13	X-RAY DIFFRACTION	Z.LIU;R.S.YEDIDI;Y.WANG;J.S.BRUNZELLE;I.A.KOVARI;L.C.KOVARI	Z.LIU;R.S.YEDIDI;Y.WANG;T.G.DEWDNEY;S.J.REITER;;J.S.BRUNZELLE;I.A.KOVARI;L.C.KOVARI	INSIGHTS INTO THE MECHANISM OF DRUG RESISTANCE: X-RAY STRUCTURE ANALYSIS OF MULTI-DRUG RESISTANT HIV-1 PROTEASE RITONAVIR COMPLEX.	BIOCHEM.BIOPHYS.RES.COMMUN. V. 431 232 2013	1:RIT	0.8M NACL, 0.1 M MES, PH 5.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 295K	1.80	0.226	0.193	P 41	45.40*45.40*104.07(90.00x90.00x90.00)	8	PQITLWQRPIVTIKIGGQLKEALLNTGADDTVLEEVNLPGRWKPKLIGGIGGFVKVRQYDQVPIEICGHKVIGTVLVGPTPTNVIGRNLMTQIGCTLNF	99	A;B	HIV-1 PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	Q000H7_9HIV1:Q000H7:1-99	
4NJV	1	CRYSTAL STRUCTURE OF MULTIDRUG-RESISTANT CLINICAL ISOLATE A02 HIV-1 PROTEASE IN COMPLEX WITH RITONAVIR	MULTIDRUG-RESISTANCE;HIV-1 PROTEASE;RITONAVIR;RIT;PROTEASEINHIBITOR;KALETRA;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	11-NOV-13	02-APR-14	X-RAY DIFFRACTION	R.S.YEDIDI;H.GARIMELLA;S.B.CHANG;J.D.KAUFMAN;D.DAS;P.T.WINGFIELD;H.MITSUYA	R.S.YEDIDI;H.GARIMELLA;M.AOKI;H.AOKI-OGATA;D.V.DESAI;;S.B.CHANG;D.A.DAVIS;W.S.FYVIE;J.D.KAUFMAN;D.W.SMITH;D.DAS;;P.T.WINGFIELD;K.MAEDA;A.K.GHOSH;H.MITSUYA	A CONSERVED HYDROGEN-BONDING NETWORK OF P2 BIS-TETRAHYDROFURAN-CONTAINING HIV-1 PROTEASE INHIBITORS (PIS) WITH A PROTEASE ACTIVE-SITE AMINO ACID BACKBONE AIDS IN THEIR ACTIVITY AGAINST PI-RESISTANT HIV.	ANTIMICROB.AGENTS CHEMOTHER. V. 58 3679 2014	2:RIT	3.0 M SODIUM CHLORIDE (PRECIPITANT), 0.1 M HEPES (BUFFER), PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.80	0.216	0.188	P 1 21 1	45.95*58.22*86.87(90.00x90.02x90.00)	8	PQITLWQRPIVTIKVGGQLKEALLDTGADDTVLEDMELPGRWKPRMIGGIGGFVKVRQYDQIPIEICGHKVIGTVLVGPTPTNIIGRNLMTQLGFTLNF	99	A;B;C;D	PROTEASE	4	Escherichia coli	Human immunodeficiency virus 1	Q9J006_9HIV1:Q9J006:1-99	
5VC0	1	CRYSTAL STRUCTURE OF HUMAN CYP3A4 BOUND TO RITONAVIR	CYTOCHROME P450;CYP3A4;MONOOXYGENASE;RITONAVIR;INHIBITOR;OXIDOREDUCTASE-INHIBITOR COMPLEX	30-MAR-17	31-MAY-17	X-RAY DIFFRACTION	I.SEVRIOUKOVA	I.F.SEVRIOUKOVA	HIGH-LEVEL PRODUCTION AND PROPERTIES OF THE CYSTEINE-DEPLETED CYTOCHROME P450 3A4.	BIOCHEMISTRY V. 56 3058 2017	1:HEM; 1:RIT	HAMPTON PEGION2 SOLUTION #15, PH 7.4, MICROBATCH, TEMPERATURE 298K	2.70	0.283	0.212	I 2 2 2	76.58*100.07*125.22(90.00x90.00x90.00)	8	MAYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGAHHHH	487	A	CYTOCHROME P450 3A4	1	Escherichia coli	Homo sapiens	CP3A4_HUMAN:P08684:23-503	
5VCE	1	CRYSTAL STRUCTURE OF THE CYSTEINE DEPLETED CYP3A4 BOUND TO RITONAVIR	CYTOCHROME P450;CYP3A4;MONOOXYGENASE;CYSTEINE MUTATION;RITONAVIR;OXIDOREDUCTASE-INHIBITOR COMPLEX	31-MAR-17	31-MAY-17	X-RAY DIFFRACTION	I.SEVRIOUKOVA	I.F.SEVRIOUKOVA	HIGH-LEVEL PRODUCTION AND PROPERTIES OF THE CYSTEINE-DEPLETED CYTOCHROME P450 3A4.	BIOCHEMISTRY V. 56 3058 2017	1:HEM; 1:RIT	PEG4000, PH 7.5, MICROBATCH, TEMPERATURE 298K	2.20	0.275	0.242	I 2 2 2	77.37*100.71*129.22(90.00x90.00x90.00)	8	MAYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFAMFDMEMHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKEAYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNITVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVAKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPSKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGAHHHH	487	A	CYTOCHROME P450 3A4	1	Escherichia coli	Homo sapiens	CP3A4_HUMAN:P08684:23-503	
5VEU	1	HUMAN CYTOCHROME P450 3A5 (CYP3A5)	INHIBITOR;COMPLEX;CYTOCHROME P450;RITONAVIR;CYP3A5;OXIDOREDUCTASE-OXIDOREDUCTASE INHIBITOR COMPLEX	05-APR-17	15-NOV-17	X-RAY DIFFRACTION	M.-H.HSU;E.F.JOHNSON	M.H.HSU;U.SAVAS;E.F.JOHNSON	THE X-RAY CRYSTAL STRUCTURE OF THE HUMAN MONO-OXYGENASE CYTOCHROME P450 3A5-RITONAVIR COMPLEX REVEALS ACTIVE SITE DIFFERENCES BETWEEN P450S 3A4 AND 3A5.	MOL. PHARMACOL. V. 93 14 2018	12:HEM; 3:RIT	PEG 3350, PEG 300, ADA, ZINC SULFATE, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 297K	2.91	0.258	0.216	P 21 21 21	148.99*198.38*234.88(90.00x90.00x90.00)	48	MALYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKFDTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISLAEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYSMDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSLFPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSIIFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVVNETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFSKKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQGLLQPEKPIVLKVDSRDGHHHH	480	A;B;C;D;E;F;G;H;I;J;K;L	CYTOCHROME P450 3A5	12	Escherichia coli	Homo sapiens	CP3A5_HUMAN:P20815:24-497	
